Powerful AIsolutions for cancerpathology diagnostic support
AI-based cancer pathology image analysis solutions Available with & without DeepDx® Viewer
5 Products
Products under development
9 Products
-
An algorithm that automatically detects and quantifies Ki-67 expression for breast cancer. Expressed strongly in tumor cell proliferation, Ki-67 can predict high risk of recurrence and poor survival of cancer.
Breast Ki-67 IHC
-
An advanced algorithm for automatic IHC scoring of HER2 in breast cancer. Through identifying and scoring tumors positive for HER2, our algorithm helps identify patients eligible for HER2 targeted therapy.
Breast HER2 IHC
-
A model that can perform automated whole-slide scoring to provide quantitative measurements of ER receptor status in breast cancer. This algorithm can be used to quickly and accurately identify breast cancer patients who are candidates for hormonal therapy, which can substantially improve their survival.
Breast ER IHC
-
A model that can perform automated whole-slide scoring to provide quantitative measurements of PR receptor status in breast cancer. This algorithm can be used to quickly and accurately identify breast cancer patients who are candidates for hormonal therapy, which can substantially improve their survival.
Breast PR IHC
-
An algorithm that detects PD-L1 expression on IHC image and quantifies it accurately for NSCLC (Non-small Cell Lung Cancer).
Lung PD-L1 IHC
-
A model that aims to establish detailed standards to identify patients with NSCLC (Non-small Cell Lung Cancer) for treatment using c-MET inhibitors. As the algorithm can detect and quantify c-MET expression more accurately, it could help to decrease inter-observer discrepancy among pathologists
Lung C-MET IHC
-
An algorithm that analyzes WSIs of breast core needle biopsies and excisional biopsies to detect breast cancer.
Breast – Biopsy
-
AnAI model for the analysis of prostate frozen sections for cancer detection.
Frozen Section (Prostate, Breast, Stomach, Lung)
-
A model that can detects cancer area on a digitized image of ovarian surgical biopsy specimen and predict the presence of BRCA 1/2 mutations.
Ovary BRCA H&E
Advanced deep learning technology to provide unmatched performance
Core Technology that sets us apart
Our patented methods have been trained on thousands of cases to yield instantaneous and precise analysis of data.
world-class patents in:
-
01
Deep learning-based diagnostics
technology -
02
Diagnostic result visualization
technology -
03
Tissue slide indexing technology
-
04
Intelligent annotation technology
Awards & Recognition
-
- Edison Awards - Silver
- DeepDx Prostate won Silver at the Edison Award 2021 in the Cellular Research & Disease Prevention category.
-
- Camelyon17 Grand Challenge
- Our research team won the first place in Camelyon17, a global image analysis competition for detection and classification of breast cancer lymph nodes metastasis.
R&D for innovation in medical AI
-
AI-based Predictive Analytics
in Cancer Pathology - Development of prediction models by combining cancer pathology image analysis with oncology clinical data
- Treatment
- DeepDx Prostate is CE-marked, and MFDS-approved for clinical use in Korea. DeepDx solutions are not cleared by the FDA and for Research Use Only (RUO) in the United States. Contact Deep Bio for more information on system configuration, functionality and indications for use.